Using Selumetinib in Advanced Uveal Melanoma

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.

Clinical Pearls

The trial exploring selumetinib was the first ever to find an agent that demonstrated efficacy for patients with advanced uveal melanoma. Even though trametinib (another MEK inhibitor) was recently approved, Carvajal says that clinical trials are still the most appropriate area for treatment with MEK inhibitors in uveal melanoma.

  • The trial exploring selumetinib was the first ever to find an agent that demonstrated efficacy for patients with advanced uveal melanoma
  • Clinical trials are still the most appropriate area for treatment with MEK inhibitors in this disease type

<<<

View all coverage from the 2013 ASCO Meeting